Literature DB >> 6382300

Properties of myelofibrosis-derived fibroblasts.

H Castro-Malaspina, S C Jhanwar.   

Abstract

Fibroblasts derived from bone marrow of patients with primary myelofibrosis and of patients with other well-differentiated myeloproliferative disorders without myelofibrosis (MPD), exhibit in vitro the same properties as fibroblasts derived from normal bone marrow. The cell density distribution, cell sedimentation rate distribution and time-dependent adherence of bone marrow fibroblast colony-forming cells (CFU-F) of MPD patients are similar to those of normals. The in vitro growth parameters, namely anchorage, serum dependence, and contact inhibition are analogous in fibroblasts derived from fibrotic and normal bone marrow. The intra- and extra-cellular distribution of fibronectin, type I, type III and type V collagens is similar in cultured marrow fibroblasts from normals, and from MPD patients with and without myelofibrosis. The plasminogen-dependent fibrinolytic activity elicited from normal and myelofibrotic marrow fibroblasts are equivalent. Moreover, marrow fibroblasts from patients with myelofibrosis do not exhibit the chromosomal abnormalities present in hematopoietic cells. These observations provide strong evidence for the absence of changes associated with neoplastic states in fibroblasts derived from fibrotic bone marrow, and support the hypothesis that myelofibrosis associated with MPD results from the abnormal interaction between hematopoietic cells and marrow collagen-producing cells, rather than from a primary disorder affecting the latter cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6382300

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  7 in total

Review 1.  The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

Authors:  Devendra Kc; Lorenzo Falchi; Srdan Verstovsek
Journal:  Ann Hematol       Date:  2017-08-14       Impact factor: 3.673

2.  Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis.

Authors:  Alessandro M Vannucchi; Alessandro Pancrazzi; Paola Guglielmelli; Simonetta Di Lollo; Costanza Bogani; Gianna Baroni; Lucia Bianchi; Anna Rita Migliaccio; Alberto Bosi; Francesco Paoletti
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

3.  Myelofibrosis: Review of clinical and pathological features in fourteen dogs.

Authors:  B Hoff; J H Lumsden; V E Valli; S A Kruth
Journal:  Can Vet J       Date:  1991-06       Impact factor: 1.008

Review 4.  Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver.

Authors:  Alessandro Malara; Vittorio Abbonante; Maria Zingariello; Annarita Migliaccio; Alessandra Balduini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-11-01       Impact factor: 2.576

5.  [Fibrosis-driving cells in patients with primary myelofibrosis and myelodysplastic syndromes with myelofibrosis].

Authors:  Y N Cai; P H Zhang; L H Fang; J Q Liu; B Li; Z F Xu; T J Qin; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-12-14

Review 6.  Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.

Authors:  Christophe Desterke; Christophe Martinaud; Nadira Ruzehaji; Marie-Caroline Le Bousse-Kerdilès
Journal:  Mediators Inflamm       Date:  2015-11-12       Impact factor: 4.711

Review 7.  Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.

Authors:  Gregor Hoermann; Georg Greiner; Peter Valent
Journal:  Mediators Inflamm       Date:  2015-10-12       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.